Study Finds Axi-Cel Benefits Older Patients with Relapsed Refractory LBCL
AJMC,
Axicabtagene ciloleucel (axi-cel; sold as Yescarta) showed longer event-free survival (EFS) and higher response rates in…
Old Age ‘Should Not Prohibit’ Cellular Therapy Use in Large B-Cell Lymphoma
Cancer Network,
The CD19-directed CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) outperformed high-dose chemotherapy and…
Axi-cel a promising second-line treatment option for older patients with relapsed or refractory LBCL (of 10)
Pediatric News ,
Publish date: April 17, 2023 Key clinical point: Axicabtagene ciloleucel (axi-cel) is an effective second-line curative-intent…